FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1498-1499 October 8, 2009 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Steinbeck, G. PubMed Citation

Despite the infusion of more than $1 billion through the American Recovery and Reinvestment Act of 2009 and the potential commitment of much more money, there will never be enough funding to perform all the comparative-effectiveness studies that we want. The depth of interest in such studies became apparent when the Committee on Comparative Effectiveness Research Prioritization of the Institute of Medicine received more than 1200 nominations of distinct topics to be among the first supported under the act.¹ Thus, a critical question is how to choose the studies that will be supported with substantial, but not unlimited, funds. How . . . [Full Text of this Article]

Source Information

From the Veterans Affairs Palo Alto Health Care System (A.M.G.) and Stanford University (A.M.G, M.A.H.) — both in Palo Alto, CA.

This article has been cited by other articles:

• (2009). Implantable Cardioverter-Defibrillators After MI: Keep the Brakes On. Journal Watch Cardiology 2009: 1-1 [Full Text]